Akebia Therapeutics (AKBA) Gross Profit (2018 - 2026)
Akebia Therapeutics' Gross Profit came in at $38.7 million for Q2 2026, down 26.4% from $52.55 million a year earlier and down 6.2% from the prior quarter.
Powered by 
Analysis
Akebia Therapeutics (AKBA) Gross Profit (2018 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Akebia Therapeutics reported Gross Profit of $174.43 million, up 15.0% year-over-year; for FY2025, it was $196.73 million, up 102.8% from FY2024.
- Going back by year, Gross Profit was $97 million in FY2024 (-19.5%), $120.47 million in FY2023 (-41.8%), $206.92 million in FY2022 (+239.3%) and $60.98 million in FY2021.
- The Q2 2026 figure represents the lowest quarterly Gross Profit since Q4 2024.
- Year-over-year, Gross Profit increased in four of the last eight quarters, with growth averaging 42.8%.
- The fastest year-over-year change in Gross Profit over five years came in Q4 2022 (growth of 489.2%), and the weakest in Q3 2022 (a decline of 68.2%).
- Business Quant data shows AKBA's Gross Profit at $41.25 million (Q1 2026), $45.09 million (Q4 2025) and $49.38 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn |
| 10 | Akebia Therapeutics | 149.86 Mn | -512.48 Mn | 30.54 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 30.54 Mn |
| Jun 30, 2026 | 38.70 Mn |
| Mar 31, 2026 | 41.25 Mn |
| Dec 31, 2025 | 45.09 Mn |
| Sep 30, 2025 | 49.38 Mn |
| Jun 30, 2025 | 52.55 Mn |
| Mar 31, 2025 | 49.71 Mn |
| Dec 31, 2024 | 26.13 Mn |
| Sep 30, 2024 | 23.27 Mn |
| Jun 30, 2024 | 26.60 Mn |
| Mar 31, 2024 | 21.00 Mn |
| Dec 31, 2023 | 37.53 Mn |
| Sep 30, 2023 | 24.04 Mn |
| Jun 30, 2023 | 39.09 Mn |
| Mar 31, 2023 | 19.82 Mn |
| Dec 31, 2022 | 59.21 Mn |
| Sep 30, 2022 | 10.43 Mn |
| Jun 30, 2022 | 107.77 Mn |
| Mar 31, 2022 | 38.59 Mn |
| Dec 31, 2021 | 10.05 Mn |
API Access
Akebia Therapeutics Gross Profit API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=gross-profit&ticker=AKBA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "gross-profit", "ticker": "AKBA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=gross-profit&ticker=AKBA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();